A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT02366143 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1202

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DRUG: Bevacizumab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Hoffmann-La Roche